Opting for αPD-1 monotherapy or prophylactic valganciclovir in CMV IgG+ patients with unresectable metastatic disease and pre-treatment expansion of CD4+ TEM cells reduces their risk of hepatitis. Here, CD4 is linked to metastatic neoplasm.